Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma.
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma are randomized into entecavir prophylaxis group or observation group. In entecavir prophylaxis group, entecavir 0.5 mg/day orally is initiate on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy. In observation group, entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Entecavir prophylaxis | Experimental | Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy. |
|
| Observation arm | Active Comparator | Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Entecavir prophylaxis | Drug | Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis | from the beginning of anti-tumor therapy to 18 months after the last cycle of anti-tumor therapy |
| Measure | Description | Time Frame |
|---|---|---|
| the incidence of hepatitis B virus maintained response, the incidence of hepatitis B virus sustained response, the incidence of hepatitis B virus relapse and hepatitis B virus relapse related hepatitis | from the beginning of anti-tumor therapy to 18 months after the last cycle of anti-tumor therapy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jun Zhu | Contact | zj@bjcancer.org | ||
| Yuqin Song | Contact | songyuqin622@sina.com |
| Name | Affiliation | Role |
|---|---|---|
| Jun Zhu | Peking University Cancer Hospital & Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University Cancer Hospital & Institute | Recruiting | Beijing | Beijing Municipality | 100142 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Observation arm | Drug | Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation. |
|
|
| 307 Hospital of the Chinese People's Liberation Army | Recruiting | Beijing | Beijing Municipality | China |
|
| 309 Hospital of the Chinese People's Liberation Army | Recruiting | Beijing | Beijing Municipality | China |
|
| Aerospace Central Hospital | Recruiting | Beijing | Beijing Municipality | China |
|
| Air Force General Hospital of the Chinese People's Liberation Army | Recruiting | Beijing | Beijing Municipality | China |
|
| Beijing Hospital | Recruiting | Beijing | Beijing Municipality | China |
|
| Cancer Institute & Hospital, Chinese Academy of Medical Sciences | Recruiting | Beijing | Beijing Municipality | China |
|
| First Hospital affiliated to General Hospital of the Chinese People's Liberation Army | Recruiting | Beijing | Beijing Municipality | China |
|
| General Hospital of Chinese People's Liberation Army | Recruiting | Beijing | Beijing Municipality | China |
|
| Peking Union Medical College Hospital | Recruiting | Beijing | Beijing Municipality | China |
|
| Peking University First Hospital | Recruiting | Beijing | Beijing Municipality | China |
|
| Peking University People's Hospital | Recruiting | Beijing | Beijing Municipality | China |
|
| Peking University Third Hospital | Recruiting | Beijing | Beijing Municipality | China |
|
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| D008223 | Lymphoma |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C413685 | entecavir |
Not provided
Not provided
Not provided